Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revisiting the PD-1 pathway
Nikolaos Patsoukis, Qi Wang, Laura Strauss, et al.
Science Advances (2020) Vol. 6, Iss. 38
Open Access | Times Cited: 406

Showing 1-25 of 406 citing articles:

The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 7, pp. 509-528
Closed Access | Times Cited: 389
Photocatalysis in the Life Science Industry
Lisa Candish, Karl D. Collins, Gemma C. Cook, et al.
Chemical Reviews (2021) Vol. 122, Iss. 2, pp. 2907-2980
Closed Access | Times Cited: 297
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 270
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 369-374
Open Access | Times Cited: 230
Thermal immuno-nanomedicine in cancer
Zhe Yang, Di Gao, Jing Zhao, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 116-134
Closed Access | Times Cited: 149
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
Xiaojie Yu, Christian M. Orr, H. T. Claude Chan, et al.
Nature (2023) Vol. 614, Iss. 7948, pp. 539-547
Closed Access | Times Cited: 79
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 60
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Immune checkpoint inhibitor combinations—current and emerging strategies
Robert J. Walsh, Raghav Sundar, Joline S.J. Lim
British Journal of Cancer (2023) Vol. 128, Iss. 8, pp. 1415-1417
Open Access | Times Cited: 49
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Deep Shah, Brian W. Soper, Lindsay S. Shopland
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 45
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 30
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Moufida Ben Nasr, Vera Usuelli, Sergio Dellepiane, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1302-1319.e12
Closed Access | Times Cited: 27
UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity
Chuan He, Xixin Xing, Hsin-Yi Chen, et al.
Molecular Cell (2024) Vol. 84, Iss. 6, pp. 1120-1138.e8
Open Access | Times Cited: 19
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 19
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
David A. Braun, Giorgia Moranzoni, Vipheaviny Chea, et al.
Nature (2025)
Open Access | Times Cited: 14
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1235-1235
Open Access | Times Cited: 3
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3285-3285
Open Access | Times Cited: 122
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Lin Zhang, Wuqian Mai, Wenyang Jiang, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 115
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity
Florian Wiede, Kun‐Hui Lu, Xin Du, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 752-773
Open Access | Times Cited: 92
Putting the brakes on phagocytosis: “don't‐eat‐me” signaling in physiology and disease
Shannon Kelley, Kodi S. Ravichandran
EMBO Reports (2021) Vol. 22, Iss. 6
Open Access | Times Cited: 71
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
Diego Pérez, Alessandro Russo, Óscar Arrieta, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 68
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Chang Liu, Navindra P. Seeram, Hang Ma
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 67
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Lin Zhang, Bo Hao, Zhihua Geng, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 66
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
Song‐Yang Wu, Ying Xu, Li Chen, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 64
PD-L1 testing by immunohistochemistry in Immuno-Oncology
Semir Vranić, Zoran Gatalica
Bosnian Journal of Basic Medical Sciences (2022)
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top